XIAMEN SPACEGEN CO., LTD. of Xiamen at MEDICA 2019 in Düsseldorf -- MEDICA - World Forum for Medicine
Manage stand orders
Select Option


No. 2041, Xizhou Road, Xike Town Tong'an District, 361100 Xiamen

This company is co-exhibitor of
China Chamber of Commerce for Import & Export of Medicines & Health Products

Hall map

MEDICA 2019 hall map (Hall 1): stand G49

Fairground map

MEDICA 2019 fairground map: Hall 1

Our range of products

Product categories

Our products

Product category: Polymerase chain reaction (PCR)

Human Oncology Multi-Gene Mutations Detection Kit

Gene Mutation and Tumor

Tumor is the neoplasm of normal tissue, of which cancer is malignant neoplasm driven by various of tumorigenesis factors. Gene mutations caused by environment and heredity (including point mutation, deletion, insertion, copy number increase, gene fusion and so on) may lead to the division and growth of normal cells out of control and finally induce the formation of tumors.

Targeted drugs are able to target the pathologic molecules in cancer cells caused by specific gene mutations, which will maximize the drug efficacy and minimize the side effects. Therefore, the detection of the patient's gene status can contribute the clinicians to select suitable target drugs.

The initiation of the tumor is usually caused by activation proto-oncogenes or inactivation suppressor oncogenes. Studies had shown that 87% of Asian patients with lung adenocarcinoma have carried known kinds of driver genes mutations, 81% of which had clear target inhibitors, thus, 66% of patients can be treated with personalized target treatments.

More Less

Product category: Polymerase chain reaction (PCR)

Human Thyroid Carcinoma RET Gene Fusions Detection Kit

Gene Mutation and Thyroid Carcinoma

Thyroid carcinoma is one of the most common malignant thyroid neoplasms, in which about 5%-40% of the patients with papillary thyroid carcinoma (PTC) are RET fusion carriers. RET gene fusion is related to ionizing radiation. Thyroid carcinoma caused by environmental exposure to ionizing radiation are thought to be associated with RET gene fusion. When RET gene fusion occurs, it is not necessary for ligand engagement to induce RET dimerization, the mutated fusion protein will activate kinase domain of itself and downstream signaling of RAS/ERK, PI3K/AKT and MAPK/JNK pathways permanently, thus leads to cancer finally.

More Less

Product category: Polymerase chain reaction (PCR)

Human EGFR Gene T790M Mutation Detection Kit

According to the detection of EGFR status for patients with NSCLC, exon 19 deletions mutations are found in 45% of the patients, and a mutation of exon 21 L858R is about 40%- 45%, while the mutations of exon 20 insertions occupies about 5%. The first and second generations of EGFR-TKI drugs are effective for patients harboured EGFR mutation menttioned above. Studies have shown that most EGFR-mutant NSCLC patients have a good response to EGFR-TKI initially. However, approximately 50-65% of the patients will have drug resistance caused by T790M mutation of EGFR after they have been treated with EGFR-TKI drugs for about 10 months.

More Less

Product category: Polymerase chain reaction (PCR)

Human Pharmacogenomics SNP Detection Kit

It is reported that the side effects of drug reactions are the major cause of global death,ranking at fourth to sixth. In China, there are 2.5 million people who were hospitalized because of adverse drug reactions per year, 200,000 people died of adverse drug reactions per year. In the United States, 2 million people who were hospitalized because of adverse drug reactions per year, more than 100,000 people died of adverse drug reactions per year. The diversities of drug metabolicenzymes and pharmacological target genotypes can bring about individual differences in drug responsiveness (including drug efficacy and adverse drug reaction) through influencing the concentration of the drug invivo, and the sensitivity of the target tissue to the drug. This kit detects the SNP sites of 23 pharmacogenomics related genes, which can guide the clinical assessment for selecting appropriate drugs and dosage for specific patients, for achieving personalized medication, improving the effectiveness and safety of drug treatment and preventing the occurrance of serious adverse drug reactions.

More Less

Product category: Polymerase chain reaction (PCR)

NGS Individualized Customization Service

Just need to provide the gene segment that you are interested in or COSMIC ID number of gene mutation, you are able to customize your exclusive NGS panel.

More Less

About us

Company details

Xiamen SpacegenCo., Ltd., integrating R & D, production, sales and advisory services, is dedicated to providing the most innovative products and services for cancer, genetic diseases and other personalized precision medical testing.We provide the products with total solution for early screening, disease diagnosis, personalized drug selection and efficacy monitoring of treatment. 

Spacegen has a very professional R&D team and is equipped with next generation sequencing platform, real time PCR platform, digital PCR platform, nucleicacid mass spectrometry platform. Thirty-two products have been developed based on the above platforms. Seventeen domestic invention patents and one international invention PCT patent have been submitted. Besides, Spcegen’s core technology RingCap® has been authorized by the State Intellectual Property Office.

More Less